Polarean Imaging PLC Result of AGM (8546S)

TIDMPOLX

RNS Number : 8546S

Polarean Imaging PLC

13 July 2020

Polarean Imaging Plc

("Polarean" or the "Company")

Result of AGM

Polarean Imaging plc (AIM: POLX), the medical--imaging technology company, with a proprietary drug--device combination product for the magnetic resonance imaging (MRI) market, announces that at the AGM held earlier today, all resolutions were duly passed.

Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:

 
 Resolution           For   Against 
 Resolution 
  1            69,040,651         0 
              -----------  -------- 
 Resolution 
  2            69,035,550     5,101 
              -----------  -------- 
 Resolution 
  3            69,040,651         0 
              -----------  -------- 
 Resolution 
  4            69,040,651         0 
              -----------  -------- 
 Resolution 
  5            69,040,651         0 
              -----------  -------- 
 Resolution 
  6            69,040,651         0 
              -----------  -------- 
 Resolution 
  7            69,010,651         0 
              -----------  -------- 
 Resolution 
  8            68,885,651   125,000 
              -----------  -------- 
 

Contacts:

 
 Polarean Imaging plc                                   www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive                                             Via Walbrook PR 
  Officer 
  Jonathan Allis, Chairman 
 
 SP Angel Corporate Finance LLP Nomad                                 Tel: [phone] 
  and Broker 
 David Hignell / Soltan Tagiev (Corporate 
  Finance) 
 Vadim Alexandre / Rob Rees (Corporate 
  Broking) 
 
 Walbrook PR                               Tel: [phone] or [e-mail] 
 Paul McManus / Anna Dunphy                             Mob: [phone] 
                                                                                       741 001 
 
 

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas ((129) Xe) as an imaging agent to visualize ventilation.(129) Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimize the imaging of (129) Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGSFSFDDESSEEW

(END) Dow Jones Newswires

July 13, 2020 09:23 ET (13:23 GMT)